The biotech company RevolKa, which is based in Tokyo, Japan and is dedicated to the development of an AI-driven protein engineering technology platform, has successfully raised US$0.7M and concluded a US$1.7M Series A funding round.
D3 and DEEPCORE jointly lead the Series A extension round.
The company intends to allocate the funds to the expansion of its drug discovery and development initiatives.
RevolKa, a biotechnology company established in April 2021, is dedicated to the development of innovative proteins that are beneficial for therapeutics and industries through the application of proprietary technology.
Read also – Powder Beauty Secures Pre-Series A Funding Round
Additionally, the organization declared the commencement of a drug discovery initiative for rare diseases on July 30, 2024. A few of its drug candidates in this program have demonstrated positive in vitro proof-of-concept.
About RevolKa
Founded in 2021 by Shiro Kataoka, RevolKa is an enthusiast of proteins, which are highly functional molecules in biological reactions. During the evolution of life, proteins have been transformed in response to environmental changes.
